A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) (IONA-MM)

April 10, 2024 updated by: Sanofi

Primary Objective:

To assess the effectiveness, in terms of overall response rate (ORR) of isatuximab patients with RRMM in routine clinical practice, within 12 months

To assess other effectiveness parameters such as progression free survival (PFS), PFS rate (PFSR), duration of response (DoR), time to response, time and intent to first subsequent therapy, rate of very good partial response or better, rate of complete response (CR) or better of isatuximab patients with RRMM in routine clinical practice

To assess the profile of patients (demographic, disease characteristics, comorbidities and prior MM treatment history) who are treated with isatuximab in routine clinical practice

To describe safety of isatuximab in routine clinical practice (based on adverse event [AE] reporting)

To assess quality of life (QoL) using the European Organization for Research and Treatment of Cancer (EORTC) 30 item core questionnaire (QLQ C30) and the accompanying 20 item myeloma questionnaire module (QLQ MY20)

Secondary Objective:

Not applicable

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Duration per participant is 2.5 years

Study Type

Observational

Enrollment (Estimated)

1200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Trial Transparency email recommended (Toll free number for US & Canada)
  • Phone Number: option 6 800-633-1610
  • Email: Contact-US@sanofi.com

Study Locations

  • Argentina
      • Cordoba, Argentina, 5016
        • Recruiting
        • Investigational Site Number : 0320002
    • Buenos Aires
      • Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1181ACH
        • Recruiting
        • Investigational Site Number : 0320001
  • Austria
      • Steyr, Austria, 4400
        • Recruiting
        • LKH Steyr - Investigational Site Number : 0400002
        • Contact:
          • Hanns HAUSER
          • Phone Number: +43505546624210
        • Principal Investigator:
          • Hanns HAUSER
      • Wien, Austria, 1220
        • Recruiting
        • Investigational Site Number : 0400003
  • Belgium
      • Anderlecht, Belgium, 1070
        • Recruiting
        • Institut Jules Bordet - Investigational Site Number : 0560001
        • Contact:
          • Meuleman
          • Phone Number: +3225413728
        • Principal Investigator:
          • Nathalie Meuleman
      • Sint Niklaas, Belgium, 9100
        • Recruiting
        • Investigational Site Number : 0560002
  • China
      • Shenzhen, China, 518053
        • Recruiting
        • Investigational Site Number : 1560001
  • France
      • Argenteuil, France, 95107
        • Recruiting
        • Centre Hospitalier Victor Dupouy - Investigational Site Number : 2500007
        • Contact:
          • Emanuelle LE RAY
          • Phone Number: +33134231566
        • Principal Investigator:
          • Emanuelle LE RAY
      • Cahors, France, 46000
        • Recruiting
        • Investigational Site Number : 2500017
      • Chambéry, France, 73000
        • Recruiting
        • Centre Hospitalier Metropole Savoie - Investigational Site Number : 2500006
        • Contact:
          • Pierre FAURI
          • Phone Number: +33479965105
        • Principal Investigator:
          • Pierre FAURI
      • Essey les Nancy, France, 54270
        • Recruiting
        • Investigational Site Number : 2500012
      • Le Mans Cedex, France, 72037
        • Recruiting
        • Centre Hospitalier Le Mans - Investigational Site Number : 2500015
        • Contact:
          • Laribi Kamel
          • Phone Number: +33255463467
        • Principal Investigator:
          • Laribi Kamel
      • Lille, France, 59800
        • Recruiting
        • Investigational Site Number : 2500013
      • Montpellier Cedex 5, France, 34295
        • Recruiting
        • Investigational Site Number : 2500004
      • Pessac cedex, France, 33604
        • Recruiting
        • Investigational Site Number : 2500009
      • Poitiers, France, 86021
        • Recruiting
        • CHU Poitiers - Hôpital la Milétrie - Investigational Site Number : 2500008
        • Contact:
          • Xavier LEULEU
          • Phone Number: +33549444201
        • Principal Investigator:
          • Xavier LEULEU
      • Reims, France, 51092
        • Recruiting
        • CHU Reims - Hôpital Robert Debré - Investigational Site Number : 2500010
        • Contact:
          • Sophie GODET
          • Phone Number: +33326783644
        • Principal Investigator:
          • Sophie GODET
      • Rouen, France, 76038
        • Recruiting
        • Investigational Site Number : 2500001
      • Saint Priest En Jarez, France, 42270
        • Recruiting
        • Investigational Site Number : 2500005
      • Saint Quentin cedex, France, 02321
        • Recruiting
        • Investigational Site Number : 2500014
      • Tarbes, France, 65013
        • Recruiting
        • Investigational Site Number : 2500016
      • Toulouse, France, 31059
        • Withdrawn
        • Investigational Site Number : 2500003
      • Vannes Cedex, France, 56017
        • Recruiting
        • Investigational Site Number : 2500011
  • Germany
      • Aschaffenburg, Germany, 63739
        • Recruiting
        • Investigational Site Number : 2760014
      • Aschaffenburg, Germany, 63739
        • Recruiting
        • Investigational Site Number : 2760016
      • Bad Liebenwerda, Germany, 04924
        • Recruiting
        • Investigational Site Number : 2760025
      • Baden-Baden, Germany, 76532
        • Recruiting
        • Investigational Site Number : 2760017
      • Bamberg, Germany, 96052
        • Recruiting
        • Investigational Site Number : 2760020
      • Bayreuth, Germany, 95445
        • Recruiting
        • Investigational Site Number : 2760018
      • Berlin, Germany, 10117
        • Recruiting
        • Investigational Site Number : 2760003
      • Berlin, Germany, 10437
        • Recruiting
        • Investigational Site Number : 2760041
      • Berlin, Germany, 10715
        • Recruiting
        • Investigational Site Number : 2760009
      • Berlin, Germany, 12200
        • Recruiting
        • Investigational Site Number : 2760022
      • Donauwoerth, Germany, 86609
        • Recruiting
        • Investigational Site Number : 2760007
      • Dortmund, Germany, 44263
        • Recruiting
        • Investigational Site Number : 2760001
      • Dresden, Germany, 01127
        • Recruiting
        • Investigational Site Number : 2760002
      • Dresden, Germany, 01307
        • Recruiting
        • Investigational Site Number : 2760035
      • Frankfurt, Germany, 60596
        • Recruiting
        • Investigational Site Number : 2760037
      • Frankfurt am Main, Germany, 60389
        • Recruiting
        • Investigational Site Number : 2760010
      • Goslar, Germany, 38642
        • Recruiting
        • Investigational Site Number : 2760015
      • Hannover, Germany, 30449
        • Recruiting
        • Investigational Site Number : 2760012
      • Herrsching, Germany, 82211
        • Recruiting
        • Investigational Site Number : 2760013
      • Koeln, Germany, 50677
        • Recruiting
        • MV Zentrum für Onkologie und Hämatologie - Investigational Site Number : 2760034
        • Contact:
          • Tilman Steinmetz
          • Phone Number: +4922109318220
        • Principal Investigator:
          • Tilman Steinmetz
      • Kulmbach, Germany, 95326
        • Recruiting
        • Investigational Site Number : 2760026
      • Leipzig, Germany, 04289
        • Recruiting
        • Investigational Site Number : 2760008
      • Magdeburg, Germany, 39104
        • Recruiting
        • Investigational Site Number : 2760011
      • Marburg, Germany, 35037
        • Recruiting
        • Investigational Site Number : 2760038
      • Muenchen, Germany, 81241
        • Recruiting
        • Investigational Site Number : 2760006
      • Mutlangen, Germany, 73557
        • Recruiting
        • Investigational Site Number : 2760042
      • Neubrandenburg, Germany, 17036
        • Recruiting
        • Dietrich-Bonhoeffer-Klinikum - Investigational Site Number : 2760044
        • Contact:
          • Hemmati
          • Phone Number: +493957753303
        • Principal Investigator:
          • Philipp Hemmati
      • Oldenburg, Germany, 26121
        • Recruiting
        • Investigational Site Number : 2760021
      • Oldenburg, Germany, 26133
        • Recruiting
        • Investigational Site Number : 2760036
      • Potsdam, Germany, 14467
        • Recruiting
        • Investigational Site Number : 2760039
      • Stolberg, Germany, 52222
        • Recruiting
        • Investigational Site Number : 2760040
      • Weilheim, Germany, 82362
        • Recruiting
        • Investigational Site Number : 2760031
      • Wuerzburg, Germany, 97070
        • Recruiting
        • Investigational Site Number : 2760019
  • Hong Kong
      • Hong Kong, Hong Kong
        • Recruiting
        • Investigational Site Number : 3440001
  • Italy
      • Bologna, Italy, 40138
        • Recruiting
        • Istituto di Ematologia e Oncologia Medica - Investigational Site Number : 3800005
        • Principal Investigator:
          • Michele CAVO
        • Contact:
          • Michele CAVO
          • Phone Number: +390512143810
      • Brescia, Italy, 25123
        • Recruiting
        • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia - Investigational Site Number : 3800007
        • Principal Investigator:
          • Angelo Belotti
        • Contact:
          • Angelo Belotti
          • Phone Number: +39303996520
      • Milan, Italy, 20132
        • Recruiting
        • Investigational Site Number : 3800003
      • Napoli, Italy, 80138
        • Recruiting
        • Investigational Site Number : 3800001
      • Novara, Italy, 28100
        • Recruiting
        • Investigational Site Number : 3800008
      • Treviso, Italy, 31100
        • Recruiting
        • Investigational Site Number : 3800010
    • Roma
      • Rome, Roma, Italy, 00137
        • Recruiting
        • Investigational Site Number : 3800002
      • Rome, Roma, Italy, 00133
        • Recruiting
        • Investigational Site Number : 3800009
  • Japan
      • Fukuoka-shi, Japan, 815-8555
        • Recruiting
        • Investigational Site Number : 3920010
      • Kamogawa-shi, Japan, 296-8602
        • Withdrawn
        • Investigational Site Number : 3920002
      • Kashiwa-shi, Japan, 277-8567
        • Withdrawn
        • Investigational Site Number : 3920007
      • Minato-ku, Japan, 105-8471
        • Recruiting
        • Investigational Site Number : 3920013
      • Okayama-shi, Japan, 701-1192
        • Recruiting
        • Investigational Site Number : 3920005
      • Osakasayama-shi, Japan, 589-8511
        • Recruiting
        • Investigational Site Number : 3920014
      • Shibukawa-shi, Japan, 377-0280
        • Recruiting
        • Investigational Site Number : 3920008
      • Suwa-shi, Japan, 392-8510
        • Recruiting
        • Investigational Site Number : 3920011
      • Yamagata-shi, Japan, 990-9585
        • Recruiting
        • Investigational Site Number : 3920001
    • Hokkaido
      • Sapporo-shi, Hokkaido, Japan, 003-0006
        • Recruiting
        • Investigational Site Number : 3920012
    • Osaka
      • Osaka-shi, Osaka, Japan, 543-8555
        • Recruiting
        • Investigational Site Number : 3920009
    • Shizuoka
      • Sunto-gun, Shizuoka, Japan, 411-8777
        • Recruiting
        • Investigational Site Number : 3920003
    • Tokyo
      • Minato-ku, Tokyo, Japan, 105-8470
        • Recruiting
        • Investigational Site Number : 3920004
      • Shibuya-ku, Tokyo, Japan, 150-8935
        • Withdrawn
        • Investigational Site Number : 3920006
  • Kuwait
      • Kuwait, Kuwait, 42262
        • Recruiting
        • Investigational Site Number : 4140001
  • Netherlands
      • Dordrecht, Netherlands, 3318 AT
        • Recruiting
        • Albert Schweitzer Ziekenhuis - Investigational Site Number : 5820001
        • Principal Investigator:
          • Mark-David LEVIN
        • Contact:
          • Mark-David LEVIN
          • Phone Number: +31786523787
  • Puerto Rico
      • Hato Rey, Puerto Rico, 00917
        • Recruiting
        • Puerto Rico Medical Research Center, LLC Site Number : 8400001
      • San Juan, Puerto Rico, 00917
        • Recruiting
        • Auxilio Mutuo Cancer Center Site Number : 8400029
  • Russian Federation
      • Volgograd, Russian Federation, 400138
        • Recruiting
        • Investigational Site Number : 6430006
  • Saudi Arabia
      • Jeddah, Saudi Arabia, 23431 6688
        • Recruiting
        • Investigational Site Number : 6820004
      • Khobar, Saudi Arabia, 34234
        • Recruiting
        • Investigational Site Number : 6820001
  • Spain
      • Granada, Spain, 18012
        • Recruiting
        • Hospital Universitario Virgen de la Nieves - Investigational Site Number : 7240010
        • Principal Investigator:
          • Maria Esther Clavero Sanchez
        • Contact:
          • Maria Esther Clavero Sanchez
          • Phone Number: +34958020000
      • Palma de Mallorca, Spain, 07120
        • Recruiting
        • Hospital Universitari Son Espases - Investigational Site Number : 7240003
        • Principal Investigator:
          • Antonia Sampol Mayol
        • Contact:
          • Antonia Sampol Mayol
          • Phone Number: +34871206268
      • Pontevedra, Spain, 36001
        • Recruiting
        • Complejo Hospitalario Universitario de Pontevedra - Investigational Site Number : 7240011
        • Principal Investigator:
          • Ana Maria Dios Loureiro
        • Contact:
          • Ana Maria Dios Loureiro
          • Phone Number: +34986800399
      • San Cristobal De La Laguna, Spain, 38320
        • Recruiting
        • omplejo Hospitalario Universitario de Canarias - Investigational Site Number : 7240007
        • Principal Investigator:
          • Sunil Lakhwani
        • Contact:
          • Sunil Lakhwani
          • Phone Number: +34922678033
      • Toledo, Spain, 45003
        • Recruiting
        • Investigational Site Number : 7240004
    • León
      • Leon, León, Spain, 24071
        • Recruiting
        • Complejo Asistencial Universitario de Leon Altos de Nava s/n. -Investigational Site Number : 7240005
        • Principal Investigator:
          • Fernando Escalante Barrigon
        • Contact:
          • Fernando Escalante Barrigon
    • Málaga
      • Malaga, Málaga, Spain, 29010
        • Recruiting
        • Hospital Regional Universitario de Malaga Hospital Regional Universitario de Malaga - Investigational Site Number : 7240006
        • Principal Investigator:
          • Maria Magdalena Alcala Pena
        • Contact:
          • Maria Magdalena Alcala Pena
          • Phone Number: +34951290000
    • Navarra
      • Pamplona, Navarra, Spain, 31008
        • Recruiting
        • Investigational Site Number : 7240009
  • Switzerland
      • Baden, Switzerland, 5404
        • Recruiting
        • Investigational Site Number : 5760003
      • Bern, Switzerland, 3010
        • Recruiting
        • Investigational Site Number : 5760001
      • Zürich, Switzerland, 8063
        • Recruiting
        • Investigational Site Number : 5760002
  • Taiwan
      • Kaohsiung, Taiwan, 833401
        • Recruiting
        • Investigational Site Number : 1580002
  • United Arab Emirates
      • Abu Dhabi, United Arab Emirates, 11001
        • Recruiting
        • Investigational Site Number : 7840002
      • Abu dhabi, United Arab Emirates, 7400
        • Recruiting
        • Investigational Site Number : 7840001
  • United Kingdom
      • Huddersfield, United Kingdom, HD3 3EA
        • Recruiting
        • Investigational Site Number : 8260004
      • Newcastle Upon Tyne, United Kingdom, NE7 7DN
        • Recruiting
        • Freeman Hospital - Investigational Site Number : 8260003
        • Contact:
          • Jennifer Young
          • Phone Number: +441912336161
        • Principal Investigator:
          • Jennifer Young
    • Nottinghamshire
      • Nottingham, Nottinghamshire, United Kingdom, NG5 1PB
        • Recruiting
        • Investigational Site Number : 8260002
    • Surrey
      • Sutton, Surrey, United Kingdom, SM2 5PT
        • Recruiting
        • Investigational Site Number : 8260005
  • United States
    • Arkansas
      • Little Rock, Arkansas, United States, 72205-7199
        • Recruiting
        • University of Arkansas Medical Sciences Site Number : 8400021
    • California
      • Fullerton, California, United States, 92835
        • Recruiting
        • St. Joseph Heritage Healthcare Site Number : 8400008
      • San Francisco, California, United States, 94143
        • Recruiting
        • University of California San Francisco (PARENT) Site Number : 8400009
    • Florida
      • Fort Lauderdale, Florida, United States, 33308
        • Recruiting
        • Holy Cross Hospital Site Number : 8400030
      • Jacksonville, Florida, United States, 32204
        • Recruiting
        • GenesisCare Site Number : 8400007
      • Lakeland, Florida, United States, 33805
        • Recruiting
        • Watson Clinic Cancer and Research Center Site Number : 8400023
      • Pembroke Pines, Florida, United States, 33024
        • Recruiting
        • Millennium Oncology Site Number : 8400025
      • Saint Petersburg, Florida, United States, 33709
        • Recruiting
        • Comprehensive Hematology Oncology Site Number : 8400026
    • Kansas
      • Garden City, Kansas, United States, 67846
        • Recruiting
        • Central Care Cancer Center Site Number : 8400006
      • Garden City, Kansas, United States, 67846
        • Recruiting
        • Central Care Cancer Center Site Number : 8400019
    • Maine
      • Lewiston, Maine, United States, 04240
        • Recruiting
        • Central Maine Medical Center Site Number : 8400031
    • Michigan
      • Farmington Hills, Michigan, United States, 48334
        • Recruiting
        • Michigan Center of Medical Research Site Number : 8400010
    • Missouri
      • Kansas City, Missouri, United States, 64114
        • Recruiting
        • AMR Kansas City Site Number : 8400016
    • New Jersey
      • Freehold, New Jersey, United States, 07728
        • Recruiting
        • Regional Cancer Care Associates, LLC - Freehold Division Site Number : 8400017
      • Howell, New Jersey, United States, 07731
        • Recruiting
        • Regional Cancer Care Associates Site Number : 8400024
      • Little Silver, New Jersey, United States, 07739
        • Recruiting
        • Regional Cancer Care Associates - Little Silver Division Site Number : 8400018
    • North Carolina
      • Winston-Salem, North Carolina, United States, 27103
        • Recruiting
        • Novant Health Forsyth Medical Center Site Number : 8400028
    • Ohio
      • Canton, Ohio, United States, 44708
        • Recruiting
        • Hematology & Oncology Associates Site Number : 8400015
      • Massillon, Ohio, United States, 44646
        • Recruiting
        • Tri County Hematology & Oncology Associates, Inc Site Number : 8400012
    • South Carolina
      • Charleston, South Carolina, United States, 29414
        • Recruiting
        • Charleston Hematology Oncology Associates, PA Site Number : 8400020
      • Greenville, South Carolina, United States, 29615
        • Recruiting
        • Prisma Health - Eastside Office Site Number : 8400011
    • South Dakota
      • Watertown, South Dakota, United States, 57201-1548
        • Recruiting
        • Prairie Lakes Health Care System, Inc Site Number : 8400002
    • Texas
      • Houston, Texas, United States, 77030-4000
        • Recruiting
        • MD Anderson Cancer Center Site Number : 8400013
      • The Woodlands, Texas, United States, 77380
        • Recruiting
        • Renovatio Clinical Site Number : 8400004

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

The source population for this study will be patients with a diagnosis of RRMM recruited from participating sites in Asia, Europe, Latin America, and North America. The study will aim to enroll up to approximately 1200 adult patients with a recorded diagnosis of RRMM from up to 150 sites. A subset of patients from sites, limited to the US only, will be recruited (up to 100 patients out of 1200), for enrichment by leveraging existing electronic medical record (EMR) technologies coupled with the electronic case report forms (eCRFs).

Description

Age ≥18 years

  • Patients with RRMM who have at least one prior line of therapy
  • Patients for whom the treating physician has made the decision to initiate isatuximab per routine practice and independently of the purpose of the study; for retrospectively enrolled patients, exposure to isatuximab treatment for a maximum of three months prior to study enrollment
  • Able to understand and complete the study-related questionnaires
  • Patient must have given signed informed consent prior to study start. For retrospectively enrolled patients who are deceased at the date of enrollment into the study, a waiver of consent will be required; patients who have started and stopped treatment up to three months before ICF are eligible .

Most important exclusion criteria for potential participants:

Patients who are receiving isatuximab for an indication other than RRMM

  • Patients who have received any other investigational drug or prohibited therapy for this study within 28 days or five half-lives from randomization, whichever is longer
  • Patients having contraindication to the isatuximab summary of product characteristics (SMPC) or package insert (PI)
  • Patients having contraindications as noted in the drug-specific local isatuximab SMPC/PI of combination drugs
  • Any country-related specific regulation that would prevent the patient from entering the study

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Cohort 1
Patients with multiple myeloma (MM) and are considered as RRMM according to the International Myeloma Working Group (IMWG) criteria
Drug: isatuximab SAR650984

Pharmaceutical form: solution for infusion

Route of administration: intravenous

Other Names:
  • Sarclisa
Drug: Pomalidomide
Pharmaceutical form: oral
Other Names:
  • Pomalyst
Drug: Dexamethasone
Pharmaceutical form: oral
Drug: Carfilzomib
Pharmaceutical form: solution for infusion

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall response rate (ORR)
Time Frame: 12 months
The proportion of patients with stringent complete response (sCR), complete response (CR), very good partial response (VGPR), and partial response (PR) as best overall response assessed by investigator using the IMWG response criteria
12 months
Progression free survival (PFS)
Time Frame: up to 18 months
Time from isatuximab start date to the date of first documentation of progressive disease (PD) (as determined by the investigator) or the date of death from any cause, whichever comes first.
up to 18 months
Progression free survival rate (PFSR)
Time Frame: up to 18 months
The proportion of patients who do not progress and are alive at specific time intervals
up to 18 months
Duration of response (DoR)
Time Frame: 12 months
Time from the date of the first response for patients achieving partial response (PR) 4 or better (PR , VGPR , CR , or sCR to the date of first documented PD (as determined by Investigator using the IMWG response criteria) or death, whichever happens first.
12 months
Time to response (TTR)
Time Frame: 12 months
Defined as the time between isatuximab start date and the onset of first response for patients achieving PR or better (sCR, CR, VGPR, or PR) assessed by investigator using the IMWG response criteria
12 months
Time to first subsequent anti-myeloma therapy
Time Frame: 30 months
Time from the initiation of isatuximab until the start of subsequent therapy or death.
30 months
Rate of very good partial response or better
Time Frame: up to 12 months
Comprising VGPR, CR, and sCR within 12 months
up to 12 months
Rate of complete response (CR) or better
Time Frame: up to 12 months
Comprising CR and sCR responses within 12 months
up to 12 months
Number of Participants with Adverse events
Time Frame: 1 month after end of treatment
Adverse events (AE) including treatment emergent adverse events (TEAE), serious adverse events (SAE) and adverse events of special interest (AESIs) according to the following parameters: associated reactions (IARs), pregnancy in a patient (or partner of a patient), symptomatic overdose, occurrence of a second malignancy, and/or neutropenia. TEAEs are defined as AEs that develop, worsen (according to the Investigator opinion), or become serious during the TEAE period infusion
1 month after end of treatment
Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Disease-Related Symptom Scales of the Quality of Life 30 item core questionnaire (QLQ-C30)
Time Frame: through end of treatment (up to approximately 2 years)
The EORTC QLQ-C30 is a brief self- or interviewer-administered patient-reported survey. This 30-item questionnaire measures the following domains: 1) global health status/QoL; 2) functional scales including physical, role, emotional, cognitive, and social functioning; and 3) symptom scales/items related to fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial impact.
through end of treatment (up to approximately 2 years)
Change from Baseline in the EORTC Multiple Myeloma Specific Quality of Life 20 item questionnaire (QLQ MY20)
Time Frame: through end of treatment (up to approximately 2 years)
The EORTC QLQ-MY20 is a validated, self -administered instrument to assess QoL in persons with MM. This 20-item questionnaire measures the following domains: symptom scales, including disease symptoms (6 items) and symptoms related to side effects of treatment (10 items); function scale and future perspective (3 items); and body image (1 item).
through end of treatment (up to approximately 2 years)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sanofi

Investigators

  • Study Director: Clinical Sciences & Operations, Sanofi

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 13, 2020

Primary Completion (Estimated)

February 23, 2026

Study Completion (Estimated)

February 23, 2026

Study Registration Dates

First Submitted

June 25, 2020

First Submitted That Met QC Criteria

July 2, 2020

First Posted (Actual)

July 7, 2020

Study Record Updates

Last Update Posted (Actual)

April 12, 2024

Last Update Submitted That Met QC Criteria

April 10, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • OBS16577

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Plasma Cell Myeloma

Clinical Trials on isatuximab SAR650984

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe